Immunome (NASDAQ:IMNM) Sees Unusually-High Trading Volume – Here’s What Happened

Immunome, Inc. (NASDAQ:IMNM) saw unusually-high trading volume on Thursday . Approximately 958,208 shares changed hands during trading, an increase of 45% from the previous session’s volume of 660,083 shares.The stock last traded at $9.84 and had previously closed at $9.35.

Analysts Set New Price Targets

IMNM has been the subject of several research analyst reports. Piper Sandler reduced their price objective on Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Stephens assumed coverage on shares of Immunome in a report on Friday, November 8th. They set an “overweight” rating and a $30.00 price target for the company. Finally, Wedbush reaffirmed an “outperform” rating and set a $33.00 price objective on shares of Immunome in a research report on Monday, January 13th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Immunome has an average rating of “Buy” and an average target price of $28.60.

Immunome Stock Performance

The company has a market capitalization of $688.49 million, a PE ratio of -1.36 and a beta of 1.90. The stock has a 50 day moving average price of $11.36 and a two-hundred day moving average price of $12.73.

Insider Buying and Selling

In related news, CEO Clay B. Siegall purchased 66,057 shares of the firm’s stock in a transaction dated Thursday, November 21st. The stock was bought at an average price of $9.54 per share, for a total transaction of $630,183.78. Following the purchase, the chief executive officer now owns 485,693 shares in the company, valued at $4,633,511.22. The trade was a 15.74 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Robert Lechleider acquired 15,805 shares of the stock in a transaction dated Thursday, November 21st. The shares were bought at an average cost of $9.48 per share, for a total transaction of $149,831.40. Following the acquisition, the insider now owns 15,805 shares in the company, valued at $149,831.40. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 102,862 shares of company stock worth $978,045. Insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On Immunome

Large investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC lifted its stake in shares of Immunome by 10.3% in the third quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock worth $50,971,000 after buying an additional 324,614 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Immunome by 217.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company’s stock worth $6,469,000 after acquiring an additional 302,916 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in Immunome by 48.1% during the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock valued at $10,684,000 after acquiring an additional 237,497 shares during the period. Geode Capital Management LLC boosted its holdings in Immunome by 13.6% during the third quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock valued at $17,657,000 after acquiring an additional 144,557 shares during the period. Finally, Point72 Asset Management L.P. grew its position in shares of Immunome by 22.2% in the third quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company’s stock valued at $6,881,000 after purchasing an additional 85,580 shares during the last quarter. Institutional investors own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.